Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 4/20 | 0.60 |
| ▸ | TCF4 | P15884 | 3/20 | 0.60 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 15/20 | 0.52 |
| ▸ | CLPP | Q16740 | 2/20 | 0.51 |
| ▸ | TCF7 | P36402 | 2/20 | 0.50 |
| ▸ | BCL9 | O00512 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14620313 | 0.93 | CTNNB1 (0.52) | CTNNB1TCF4CREBBPCYP3A4CLPP | |
| SCHEMBL10291397 | 0.92 | CTNNB1 (0.52) | CTNNB1TCF4CREBBPCYP3A4CLPP | |
| SCHEMBL10227752 | 0.92 | CYP3A4 (0.60) | CTNNB1TCF4CREBBPCYP3A4CLPP | |
| SCHEMBL751020 | 0.92 | CYP3A4 (0.60) | CTNNB1TCF4CREBBPCYP3A4CLPP | |
| SCHEMBL748379 | 0.91 | CLPP (0.63) | CTNNB1TCF4CREBBPCYP3A4CLPP | |
| SCHEMBL748459 | 0.90 | TCF4 (0.55) | CTNNB1TCF4CREBBPCYP3A4CLPP | |
| SCHEMBL12222464 | 0.89 | TCF4 (0.47) | CTNNB1TCF4CREBBPCYP3A4CLPP | |
| SCHEMBL749276 | 0.88 | CTNNB1 (0.77) | CTNNB1TCF4CREBBPCYP3A4CLPP | |
| SCHEMBL748099 | 0.84 | CYP3A4 (0.56) | CTNNB1TCF4CREBBPCYP3A4CLPP | |
| SCHEMBL747980 | 0.83 | CLPP (0.65) | CTNNB1TCF4CREBBPCYP3A4CLPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138337-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-03-20 | — | — | US | disclosed |
| US-8101751-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-01-24 | — | — | US | disclosed |
| US-8049008-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2011-11-01 | — | — | US | disclosed |
| US-7932384-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2011-04-26 | — | — | US | disclosed |
| US-20100240662-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2010-09-23 | — | — | US | disclosed |
| US-20100222303-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2010-09-02 | — | — | US | disclosed |
| US-20100081655-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2010-04-01 | — | — | US | disclosed |
| US-7671054-B1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2010-03-02 | — | — | US | disclosed |
| US-20100029630-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | Chongwae Pharma Corporation (KR) | 2010-02-04 | — | — | US | disclosed |
| US-7576084-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2009-08-18 | — | — | US | disclosed |
| US-7566711-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2009-07-28 | — | — | US | disclosed |
| US-20070043052-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-02-22 | — | — | US | disclosed |
| US-20070021425-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222303-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, WNT3, APC | CTNNB1 9/4885TCF4 60/4885CREBBP 346/4885 |
| US-20100029630-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | CTNNB1 14/4885TCF4 50/4885CREBBP 196/4885 |
| US-20070043052-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | CTNNB1 14/4885TCF4 50/4885CREBBP 196/4885 |
| US-20100081655-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | CTNNB1 14/4885TCF4 50/4885CREBBP 196/4885 |
| US-20100240662-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, WNT3, APC | CTNNB1 9/4885TCF4 60/4885CREBBP 346/4885 |
| US-20070021425-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | CTNNB1 14/4885TCF4 50/4885CREBBP 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.